PROVEN TO HELP PEOPLE WITH ATTR-CM
People receiving AMVUTTRA® (vutrisiran) lived longer and had fewer hospital visits
Effectiveness was determined by comparing the results of people treated with AMVUTTRA to those who received placebo (a treatment without any medication). The main measure of effectiveness was the combined risk of death and heart-related hospital stays and urgent visits over 3 years.
After the first 3 years of the study, people receiving placebo switched to AMVUTTRA so that everyone still in the study received AMVUTTRA for up to an additional 6 months. The study then measured the risk of death over 3.5 years, comparing the original AMVUTTRA group to the original placebo group.
*Hospital visits included hospital stays and urgent visits.
†Most deaths were heart-related.
†Most deaths were heart-related.
AMVUTTRA slowed disease progression compared to placebo‡
The study also measured physical activity and health-related quality of life at 2.5 years.
People receiving AMVUTTRA were able to walk 72 feet farther than people receiving placebo.
These results are based on the 6-minute walk test (6-MWT),‡ which measures the distance someone can walk in 6 minutes.
People receiving AMVUTTRA reported a significantly better health status and health-related quality of life compared to placebo.
These results were measured using a questionnaire called KCCQ,‡ which asked patients about their heart failure symptoms, ability to perform routine tasks and participate in social activities, and the impact heart failure had on their quality of life.
KCCQ=Kansas City Cardiomyopathy Questionnaire.
‡Patients receiving AMVUTTRA and patients receiving placebo walked a shorter distance and had lower KCCQ overall summary scores than at the start of the study.
Ask your doctor what these results may mean for you.
Build Your Personalized Discussion Guide
The Doctor Discussion Guide is a personalized tool that can help you have more informative conversations with your doctor about your specific needs as you manage ATTR-CM.
Start by answering the following questions. If you're the care partner of someone with ATTR-CM, complete this guide together.
Or, you can download a version to print and fill out.
By submitting this form, I agree to the Alnylam Privacy Policy. I am 18 years or older, a US resident, and consent to the processing of my personal data per the terms outlined in the Data Privacy Notification and Consent.
